All PlansCoverageLow impact
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Blue Cross & Blue Shield of Mississippi·Hematology, Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage criteria for allogeneic hematopoietic cell transplantation (allo-HCT) for patients with myelodysplastic syndromes and myeloproliferative neoplasms. The policy provides detailed medical background and treatment guidelines for these blood disorders, including when transplantation may be considered as a curative treatment option.
Action Required
Review policy for reference when encountering claims for allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes or myeloproliferative neoplasms. Ensure proper documentation of patient eligibility criteria including age, performance status, medical comorbidities, and disease severity when submitting related claims.